TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02779127

Intervention type: OTHER
Group type: OTHER
Intervention: Medical interrogatory
Description: Cardiovascular risk, medical history, known pathologies and actual treatments are evaluated

Intervention type: OTHER
Group type: OTHER
Intervention: Medical interrogatory
Description: Cardiovascular risk, medical history, known pathologies and actual treatments are evaluated

Intervention type: OTHER
Group type: OTHER
Intervention: Medical examination
Description: Systolic blood pressure, diastolic blood pressure, cardiac frequency, pulse palpation, hearth and pulmonary auscultation

Intervention type: OTHER
Group type: OTHER
Intervention: Medical examination
Description: Systolic blood pressure, diastolic blood pressure, cardiac frequency, pulse palpation, hearth and pulmonary auscultation

Intervention type: OTHER
Group type: OTHER
Intervention: Specific bioassay
Description: Exhaled carbon monoxide measure and nicotine in the urine are evaluated

Intervention type: OTHER
Group type: OTHER
Intervention: Specific bioassay
Description: Exhaled carbon monoxide measure and nicotine in the urine are evaluated

Intervention type: OTHER
Group type: OTHER
Intervention: Endothelial function evaluation
Description: Endothelial function evaluation done by echotracking determining the basale flow mediated dilatation

Intervention type: OTHER
Group type: OTHER
Intervention: Endothelial function evaluation
Description: Endothelial function evaluation done by echotracking determining the basale flow mediated dilatation

Intervention type: OTHER
Group type: OTHER
Intervention: General bioassay
Description: Fasting bioassay evaluating total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, creatine, transaminases, gamma glutamyl transferases, fibrinogen, reactive protein C, blood count and sedimentation rate.

Intervention type: OTHER
Group type: OTHER
Intervention: General bioassay
Description: Fasting bioassay evaluating total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, creatine, transaminases, gamma glutamyl transferases, fibrinogen, reactive protein C, blood count and sedimentation rate.
Study: NCT02249156

Intervention type: BEHAVIORAL
Intervention: Financial incentive for choosing a lower-cost provider
Description: Employees of the intervention group receive money (either as a payment to their health savings account or directly as a check) if they obtain a radiology test or laboratory test from what a low-cost or rewards provider. The amount of money per test varies by the employer and type of test. A provider is identified as low-cost or rewards if their costs are in the lowest 10-20% among all providers in the community. Again there is a range because the relative cutoff has varied across the employers that have implemented this program.
Study: NCT04798560

Intervention type: PROCEDURE
Intervention: Pancreaticoduodenectomy
Description: Patients udergo pancreaticoduodenectomy for periampullary tumors. All of them are observed for developing POPF
Study: NCT03028649

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: β-hydroxy-β-methylbutyrate and a placebo supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-hydroxy-β-methylbutyrate and a placebo supplementation
Study: NCT05342870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Following a sequential allocation scheme, the dexmedetomidine dose for each patient was determined by the Dixon up-and-down method. The dexmedetomidine dose for the first patient was 0.5 µg/kg. The dose was then adjusted in 0.1 µg/kg increments for the following patients depending on the success of the previous patient's block. If a patient experienced tourniquet pain prior to T0 + 50 minutes the next patient received a higher dose. If a patient did not experience pain at T0 + 50 minutes of tourniquet time the dose for the following patient was decreased. Identical syringes containing the solution mix were prepared by the principal investigator and handed to the blinded anesthesiologist in the room. Stopping rules were set at 6 independent crossovers in the same direction (no pain to pain or pain to no pain), with a minimum number of 20 patients
Study: NCT02074150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 24
Description: Efficacy of Botox subdermally at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efficacy of Botox subdermally at Week 24
Description: Efficacy of Botox subdermally at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
Study: NCT00640497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IT-Combination
Description: The treatment consists of a standard dose of 4 infusions of IT-combination (4 mg/m2), given 48-hours apart over a 4-hour period. The IT-combination is a combination of two immunotoxins. One immunotoxin is a mAb anti-CD3 conjugated to recombinant ricin A chain and the other immunotoxin is a mAb anti-CD7 conjugated to recombinant ricin A chain.
Study: NCT03968835

Intervention type: OTHER
Intervention: Bacitracin
Description: For the first 30 people, bacitracin will be applied and covered with xeroform and gauze.
Study: NCT03188276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ledipasvir-Sofosbuvir
Description: 15 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir-Sofosbuvir
Description: 17 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
Study: NCT00334893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eribulin mesylate
Description: Given IV
Study: NCT01836900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis
Description: Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic hemostasis
Description: Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution
Study: NCT03968835

Intervention type: OTHER
Intervention: Skin Graft
Description: For the next 30 patients, the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft.
Study: NCT02652156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 60 ml Bupivacaine 0.25% will be drawn via 60 ml Syringe. The syringe will be connected and a 10ml flush syringe containing 10ml 0.9% Normal Saline (NS) will be connected to the end of an IV extension set via a 3-way stopcock and Luer lock connections. The Bupivacaine 0.25% syringe will be connected to the stopcock. The distal end of the IV connection will be connected to the injection needle. The entire setup will be flushed with 0.9% NS via flush syringe. The TAP space will also be located under ultrasound guidance and verified by using the 0.9% NS flush syringe. Once in the TAP space, 30 ml Bupivacaine 0.25% will be injected into the TAP space. This dose will be decreased to 25 ml for patients under 70 kg. The process will be repeated on the opposite side TAP block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel®
Description: 20 ml Exparel (266 mg) will be drawn into a 20 ml syringe. A 20 ml Bupivacaine 0.25% syringe and the syringe containing the Exparel solution will be connected to the end of an IV extension set via a 3-way stopcock. The IV connection will be connected to the injection needle. The setup will be flushed with the Bupivacaine syringe. The TAP space will be located under ultrasound guidance. 133mg of Exparel will be injected into the TAP space. After injection, the syringe will be exchanged for the Bupivacaine syringe and 20ml Bupivacaine injected into the space. The process will be repeated on the opposite side TAP block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 40 ml Bupivacaine 0.25% will be drawn via two 20ml Syringes. A Bupivacaine 20ml syringe will be connected to an IV extension via a 3-way stopcock and Luer lock. The IV will be connected to an injection tuohy needle and flushed with NS. The TAP space will be located using ultrasound guidance. 15 ml Bupivacaine 0.25% will be injected. A catheter will be threaded through the tuohy needle into the TAP space. 5ml Bupivacaine 0.25% will then be injected. The catheter will be secured via standard technique. The process will be repeated for the opposite side. Patients will receive a filled ON-Q system. The ON-Q system contains Ropivacaine 0.2%. The pump will run at 7 ml/hr. per side.
Study: NCT00342849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succimer
Description: Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead, arsenic and mercury. The drug undergoes limited absorption in the gastrointestinal tract and then is rapidly metabolized to mixed disulfides which are eliminated in the urine. Blood levels decline slowly with an apparent elimination half-life of about 48 hours in adults.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02265718

Intervention type: DRUG
Intervention: Ritalin
Description: 1 - 20 mg tablet taken once on Day 0 and taken once on Day 28

Intervention type: DRUG
Intervention: Placebo
Description: 1 - matching tablet taken once on Day 0 and once on Day 28

Intervention type: DRUG
Intervention: Ritalin
Description: 1 - 20 mg tablet taken once on Day 0 and taken once on Day 28

Intervention type: DRUG
Intervention: Placebo
Description: 1 - matching tablet taken once on Day 0 and once on Day 28
Study: NCT00038571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS341 (Bortezomib)
Description: 1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS341 (Bortezomib)
Description: 1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.
Study: NCT02357394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arabin Pessary
Description: Arabin pessary is a ring manufactured from medical grade silicone. It comes in 13 different sizes. Participants will be fitted to the appropriate size by the study team.
Study: NCT03552172

Intervention type: OTHER
Intervention: Physical activity
Description: PHYSICAL ACTIVITY: Rhythm of meetings, number of meetings, place of meetings

Intervention type: OTHER
Intervention: Absence of or suspended physical activity
Description: the brakes responsible for a stop or lack of practice
Study: NCT03775642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention video
Description: The intervention video will employ the debiasing strategies. It will avoid directly articulating contraception-related myths, but instead will provide a limited number of alternative explanations related to IUD and implant safety.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control video
Description: The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration
Study: NCT04087733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZODROP
Description: 3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the contralateral eye will be treated with a saline solution and it will serve as a control. Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
Study: NCT00677807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
Study: NCT02319538

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total thyroidectomy performed
Description: Surgery combined with standard thyroxine treatment
Study: NCT02012595

Intervention type: OTHER
Intervention: [11C]donepezil PET
Description: Positon Emission Tomography (PET) imaging of acetylcholinesterase using the ligand \[11C\]donepezil

Intervention type: OTHER
Intervention: [11C]donepezil PET
Description: Positon Emission Tomography (PET) imaging of acetylcholinesterase using the ligand \[11C\]donepezil
Study: NCT03160053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB-UVB
Description: NB-UVB has an emission spectrum in the ultraviolet B range of 290-320 nm. The system consists of a light source, a spot handpiece, and a light guide that connects the handpiece to the light source. The light source has a Start/Stop switch for light beam activation. Activation can also be controlled remotely with a foot switch. The light source has a timer and an output level control to adjust the intensity of the ultraviolet light. This will be calibrated using a manufacturer-provided UV meter prior to every treatment to ensure accurate doses of ultraviolet light.
Study: NCT00983580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eflornithine
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Telephone-Based Intervention
Description: Ancillary studies
Study: NCT01482767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-Interferon Alfa 2b (PEG-IFN)
Description: 1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-Interferon Alfa 2b (PEG-IFN)
Description: 1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
Study: NCT02718209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mid-Infrared Spectroscopy with ATR
Study: NCT00473200

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: S-adenosylmethionine
Description: 1200 mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: S-adenosylmethionine
Description: 1200 mg daily
Study: NCT06209827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention for reducing benzodiazepines long-term use.
Description: Comprehensive, multicomponent intervention utilizing education and support for benzodiazepines.~Family doctor, nurse, community pharmacist and social workers: carried out informative discussion with the patient with by providing educational material. They informed patients about the advantages, disadvantages and alternatives to benzodiazepines including a descending benzodiazepines schedule to minimize withdrawal symptoms. It briefly explained the professionals' concerns about the continued use of benzodiazepines and offers possible solutions.~If the patient requested a withdrawal, he/she was referred to the doctor.
Study: NCT01969955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel
Description: Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
Study: NCT02206035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant.
Study: NCT00490815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide
Description: 0.5 mg fluocinolone acetonide intravitreal insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide
Description: 0.2 mg fluocinolone acetonide intravitreal insert
Study: NCT01103661

Intervention type: DEVICE
Group type: OTHER
Intervention: Numeris®-AF Guided Coagulation System with VisiTrax®
Description: Combined epicardial / endocardial procedure using the nContact Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the St. Jude Medical Therapy™ Cool Path™ Ablation Catheter endocardially.
Study: NCT05850637

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: adjuvant ultra-hypofractionated radiotherapy
Description: adjuvant ultra-hypofractionated radiotherapy for the treatment of early and locally advanced breast cancer
Study: NCT02449733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condom choices
Description: Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
Study: NCT01482767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Description: 800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response
Study: NCT02449733

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condom choices
Description: Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condom-compatible lubricant choices
Description: Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condom-compatible lubricant choices
Description: Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples HIV counseling and testing (CVCT)
Description: Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couples HIV counseling and testing (CVCT)
Description: Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
Description: FTC/TDF is a once daily oral tablet taken with or without food. The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).~For men who meet eligibility criteria, Pre-exposure prophylaxis (PrEP) with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit.
Study: NCT02074150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Botox intramuscularly
Description: Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Botox intramuscularly
Description: Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Botox intramuscularly
Description: Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.